Aspirin Raises Cancer Death Risk in Older Adults — What the Latest Trials Reveal
Decades of aspirin optimism are being upended. New trial data shows low-dose aspirin may increase cancer mortality in older adults.
Summary
Aspirin was once celebrated for preventing heart attacks and potentially reducing cancer risk, making it a staple of preventive medicine. But a wave of new evidence — including the ASPREE trial and its 2026 follow-up — is challenging that consensus. In older adults without prior cardiovascular disease, low-dose aspirin not only failed to reduce all-cause mortality but was associated with increased cancer mortality. A 2026 Cochrane Library review further complicated the picture, while a 2025 Nature study offered a possible mechanism by which aspirin might still prevent cancer metastasis via platelet pathways. The current guidance has shifted: aspirin is no longer broadly recommended for primary prevention, though it may still hold value for specific high-risk groups like Lynch syndrome patients.
Detailed Summary
Aspirin has been one of medicine's most trusted tools for decades, championed for its ability to reduce cardiovascular events and even lower cancer risk. Early observational data and meta-analyses — including landmark work by Rothwell and colleagues — suggested that daily low-dose aspirin could meaningfully cut cancer incidence and mortality. The U.S. Preventive Services Task Force even endorsed aspirin for colorectal cancer prevention in 2016, cementing its status as a longevity-adjacent intervention.
The tide began turning with the ASPREE trial, a large randomized controlled trial of over 19,000 older adults in Australia and the U.S. Published in the New England Journal of Medicine in 2018, ASPREE found that aspirin provided no benefit for disability-free survival and was associated with higher rates of major bleeding. More strikingly, aspirin-treated participants showed increased all-cause mortality, driven largely by cancer deaths — a deeply counterintuitive finding.
The 2026 ASPREE follow-up, published in JAMA Oncology, extended these observations and confirmed that low-dose aspirin significantly increased cancer mortality risk among older adults. This was echoed by a 2026 Cochrane review examining aspirin and NSAIDs for colorectal cancer prevention, which added further nuance to the risk-benefit calculus. The USPSTF has since withdrawn its colorectal cancer prevention recommendation for aspirin.
Yet the science is not entirely one-directional. A 2025 Nature study identified a specific mechanism — aspirin's suppression of platelet-derived TXA2, which in turn enhances T-cell anti-tumor immunity — suggesting aspirin may still reduce cancer metastasis in certain contexts. Lynch syndrome patients continue to show benefit from aspirin in long-term follow-up data.
For longevity-conscious individuals, the key implication is that blanket aspirin use in older, healthy adults appears unjustified. Personalized risk assessment — weighing cardiovascular history, cancer predisposition, and bleeding risk — is now essential before any aspirin recommendation.
Key Findings
- ASPREE trial found low-dose aspirin increased cancer mortality in healthy older adults, contradicting earlier optimism.
- 2026 JAMA Oncology follow-up confirmed aspirin significantly raises cancer death risk in adults over 65.
- USPSTF withdrew colorectal cancer prevention endorsement for aspirin following accumulating trial evidence.
- A 2025 Nature study shows aspirin may still reduce metastasis by boosting T-cell immunity via platelet TXA2 suppression.
- Lynch syndrome patients remain a high-risk group where aspirin prophylaxis shows continued long-term benefit.
Methodology
Dr. Brad Stanfield is a New Zealand-based general practitioner with a strong track record of translating peer-reviewed longevity research for a lay audience. This video synthesizes multiple high-quality sources including NEJM, Lancet, JAMA Oncology, and a 2026 Cochrane review. The format appears to be a narrated research explainer with timestamped sections covering trial history, findings, and clinical implications.
Study Limitations
This summary is based on the video description and referenced paper titles only, as no transcript was available — specific data points, effect sizes, and the presenter's exact conclusions could not be verified. Viewers should consult the linked primary sources, particularly the 2026 ASPREE follow-up in JAMA Oncology and the Cochrane review, before drawing clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: